Skip to main content
. 2019 Nov 26;38:474. doi: 10.1186/s13046-019-1442-2

Table 2.

IC50 of Sorafenib and nanaomycin in Hep3B naïve cells and Hep3Bresistant cells

Drugs (μM) Inhibitory concentration, IC50 (μM)
Hep3B naive cells Hep3B resistant cells
Sorafenib 9.56 ± 1.77 15.7 ± 3.11
Nanaomycin 5.56 ± 3.19 7.48 ± 5.92
Sorafenib + Nanaomycin 2 6.38 ± 0.81 7.71 ± 0.88
Sorafenib + Nanaomycin 5 3.01 ± 0.75 4.68 ± 0.95
Sorafenib + Nanaomycin 10 1.42 ± 0.20 2.06 ± 0.43